Safety & Efficacy of Eyecyte-RPEβ’ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. β StellaPhase 1 β Early testing in a small group of people (usually 20β80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
India
Shri Ganapati Netralaya, JΔlna, Maharashtra All India Institute of Medical Sciences, Delhi, New Delhi L V Prasad Eye Institute, Hyderabad, Telangana Last updated September 2024